Molecular Genetics & Genomic Medicine: New Open Access Journal Launched by Wiley
News Nov 06, 2012
Dr. Muenke, a renowned medical geneticist, trained in pediatrics in his native Germany and then pursued postdoctoral fellowship training in human and clinical genetics at Yale and the University of Pennsylvania. He is now based at a leading research organization in Bethesda, USA.
Dr. Muenke’s group identified several genes important in craniofacial disorders including one of the most common, now termed Muenke syndrome. More recently, his lab has identified susceptibility genes for the most common childhood behavioral disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), with further research focused on predicting severity, treatment, and long-term outcome.
Working alongside an international editorial board of experts in diverse areas of human and medical genetics and genomics, Dr. Muenke will oversee the rigorous peer-review and evaluation of articles submitted for publication in MGGM.
“I am extremely excited about being the founding editor of this new journal,” says Dr. Muenke. “Since there is not a single disorder that does not have a genetic origin, I believe that the fields of molecular genetics and genomic medicine will be expanding into virtually all medical specialties. MGGM will grow as well, with articles on diseases from diagnosis to treatment, as a step toward personalized medicine.”
Molecular Genetics & Genomic Medicine is the latest addition to Wiley’s portfolio of genetics journals and will benefit from relationships with widely respected titles including the American Journal of Medical Genetics and Human Mutation.
“We’re delighted to expand our open access portfolio with the addition of this important new journal,” said Rachel Burley, Vice President and Director, Open Access, Wiley. “Under the expert editorial leadership of Dr. Muenke, Molecular Genetics & Genomic Medicine will make a valuable contribution to the literature.”
The journal is open to submissions now and will publish online in spring 2013. Please visit the journal’s website www.MGGMjournal.com for further information and future updates.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018